Back to News
Market Impact: 0.5
Lilly’s Newest Bull Says Near 300% Rally Is Only the Beginning
Source: Bloomberg
Healthcare & BiotechCompany FundamentalsInvestor Sentiment & Positioning
Eli Lilly shares have risen about 300% since approval of its first GLP-1 medicine more than four years ago, lifting the company above a $1 trillion market capitalization. The gain makes Lilly the world's most valuable pharmaceutical company, underscoring the exceptional investor response to its GLP-1 franchise.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
LLY0.90
More News
- Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy?
- Eli Lilly Stock: Is It Still a Buy at $1,400?
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear